Analyst Scoreboard: 8 Ratings For Privia Health Gr
Portfolio Pulse from Benzinga Insights
In the last three months, 8 analysts have rated Privia Health Gr (NASDAQ:PRVA), with recent ratings showing a mix of bullish to indifferent sentiments. The average 12-month price target has been adjusted to $27.25, down from $32.14, reflecting a 15.21% decline. Analysts from firms like Canaccord Genuity, JP Morgan, and Barclays have adjusted their ratings and price targets, indicating a varied outlook on the company's future performance. Privia Health Gr has shown notable revenue growth of 20.97% as of December 31, 2023, and outperforms industry averages in net margin, ROE, and ROA, with a very low debt-to-equity ratio.
March 19, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Privia Health Gr has received mixed analyst ratings with a revised average 12-month price target of $27.25, indicating a cautious but still optimistic outlook. The company's strong financial performance, including significant revenue growth and superior profitability metrics, positions it favorably despite the lowered price targets.
The mixed analyst ratings and the adjustment in price targets reflect a cautious outlook for PRVA in the short term. However, the company's strong financial performance, including high revenue growth and profitability metrics, could mitigate negative impacts and provide a stable foundation for its stock price. The lowered price targets suggest a recalibration of expectations rather than a fundamental weakness, making the short-term impact neutral.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100